Medical device designer Integrity Application recently announced that it has made substantial upgrades to its innovative glucose monitoring device. The company believes that the new technological advancements will greatly improve ease of use and patient compliance among diabetics who need to monitor glucose measurement daily.
GlucoTrack model DF-F is a new non-invasive glucose measurement and tracking device developed by Integrity Application that combines ultrasonic, electromagnetic and thermal technologies. It is a battery-operated device that includes a Personal Ear Clip (PEC), which is clipped on the earlobe, allowing its sensors to be able to detect glucose levels in the blood. This new technology recently received a CE Mark approval in the European Union from Dekra Certification B.V., and the device is now able to provide results in only thirty minutes, requiring just three finger sticks for an accurate reading. Integrity believes that decreasing the calibration time is an advantage of the GlucoTrack DF-F, which allows the device to be more practical and usable.
The latest updates to the GlucoTrack model DF-F are expected to improve user experience and make glucose control easier for diabetics and people in the pre-diabetic stage. According to Prof. Lutz Heinemann, Ph.D, Chairman of Integrity’s Scientific Advisory Board, “The updated intended use is extremely significant for the Company; providing those suffering from pre-diabetes a tool to monitor his or her glucose levels is crucial for postponing, or even preventing diabetes from developing.”
Integridy believes that introducing this device to the diabetes market will improve quality of life for diabetics by enabling them to avoid the pain and discomfort of conventional (invasive) spot finger stick devices without increasing costs. The CEO of the company noted that “receiving the CE Mark approval for these improvements is extremely exciting for us. We believe that a calibration process requiring only three finger stick measurements, takes less than thirty minutes and still valid for six months is a major breakthrough for non-invasive glucose monitoring. In addition, receiving approval to market our device to pre-diabetics, practically doubles our addressable potential market. We are excited about bringing the device to the market and the opportunity that lies ahead of us.”
Besides the CE Mark approval for the GlucoTrack model DF-F in Europe, which was granted in March 2014, now Integrity Application is working to receive Food and Drug Administration approval for GlucoTrack Model DF-F in the United States. Integrity Application is a medical device company that designs, develops and commercializes non-invasive glucose monitoring devices to be used by people with diabetes or with high risk of becoming diabetic.